Hostname: page-component-cd9895bd7-mkpzs Total loading time: 0 Render date: 2024-12-19T16:32:11.283Z Has data issue: false hasContentIssue false

2178 – Psychosis Following Itraconazole Therapy - a Case Report And Literature Review

Published online by Cambridge University Press:  15 April 2020

A. Mohandas
Affiliation:
Sussex Partnership NHS Foundation Trust, Worthing
B. Bhuwan Roy
Affiliation:
South London and Maudsley NHS Foundation Trust, London
A. Sapara
Affiliation:
Kent & Medway NHS & Social Care Partnership Trust, West Malling, UK

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The authors would like to report on the case of an individual who developed psychosis, following pulse therapy of Itraconazole. We discuss his clinical presentation, history and similar reports in literature on Itraconazole.

Methods

Case-report, Literature review, Discussion.

Results

Mr.X was a 36 year old male who developed an acute psychotic episode after starting his second course of pulse treatment of Itraconazole. Subsequently he had three inpatient admissions for his psychosis, in which he was treated informally

  1. - initially with Olanzapine and Quetiapine, and following the third admission with Clozapine.

Discussion

In the back ground of a negative history of any previous psychotic episode, no family history of psychosis or any mental illness, no concordant illicit substance abuse, and the emergence of clear cut psychotic symptoms at the age of 36 following treatment with a course of oral Itraconazole, our opinion is that Itraconazole has possibly contributed to the development of psychosis in a potentially vulnerable individual. Our literature review revealed only very few case reports of Itraconazole associated psychotic disorder.

Conclusion

This case highlights, although rare, the potential risk of idiosyncratic reactions and psychiatric manifestations associated with the antifungal agent Itraconazole. We recommend increased awareness amongst clinicians about the potential idiosyncratic reaction and risk of psychosis associated with Itraconazole and also the importance in highlighting such cases for the awareness of the public as well as clinicians.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.